Expanding the immunotherapy roadmap for hepatocellular carcinoma

Marina Baretti; Amy K Kim; Robert A Anders

doi:10.1016/j.ccell.2022.02.017

Expanding the immunotherapy roadmap for hepatocellular carcinoma

Cancer Cell. 2022 Mar 14;40(3):252-254. doi: 10.1016/j.ccell.2022.02.017.

Authors

Marina Baretti¹, Amy K Kim², Robert A Anders³

Affiliations

¹ Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
² Division of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
³ Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: [email protected].

Abstract

In a recent Lancet Oncology article, Yau et al. report the CheckMate 459 trial results. This is the first phase III trial comparing the single-agent anti-programmed death protein 1 (PD-1) therapy nivolumab to the tyrosine kinase inhibitor sorafenib for treatment-naive patients with advanced hepatocellular carcinoma.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Carcinoma, Hepatocellular* / drug therapy
Carcinoma, Hepatocellular* / pathology
Humans
Immunologic Factors
Immunotherapy / methods
Liver Neoplasms* / drug therapy
Liver Neoplasms* / pathology
Nivolumab / pharmacology
Nivolumab / therapeutic use
Sorafenib / therapeutic use

Substances

Immunologic Factors
Nivolumab
Sorafenib

Grants and funding

P30 CA006973/CA/NCI NIH HHS/United States